BRAF and non-small cell lung carcinoma: Another strength is the production of original data from a large number of patients (271 patients harboring BRAF alterations taking into account both cohorts), considering the rarity of these alterations in NSCLC; moreover, many BRAF alterations of class 2 and 3 have not been previously described and analyzed in patients with NSCLC.